Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
clinical trials
life sciences
national blog main
alnylam pharmaceuticals
archive
boston
boston blog main
boston top stories
drugs
medical
onpattro
patisiran
rna interference
san francisco blog main
san francisco top stories
acute hepatic porphyrias
akcea therapeutics
akin akinc
aminolevulinic acid
andrew fire
cannabidiol
craig mello
dravet syndrome
epidiolex
fen-phen
fenfluramine
givosiran
gw pharmaceuticals
hereditary transthyretin amyloidosis
inotersen
john maraganore
lennox-gastaut syndrome
national top stories
new york blog main
new york top stories
nobel prize
paul matteis
pfizer
recalls
What
drug
6
×
fda
6
×
pharmaceuticals
6
×
medicine
approved
ago
alnylam
consumers
medication
recall
rnai
weeks
acella
adamis
administration
advised
afternoon
alerted
allergy
alnylam’s
alternative
approval
battle
blood
cancer
cannabis
cheaper
clear
compete
corporation
cost
criticized
data
derivative
development
directly
discovering
epilepsy
epipen
expanding
Language
unset
Current search:
pharmaceuticals
×
fda
×
drug
×
@slashgear.com
3 years ago
Popular thyroid drug recalled because it’s ‘super potent’ says FDA
@slashgear.com
4 years ago
High blood pressure drug recall expands again over cancer risk
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
@theverge.com
6 years ago
Cheaper alternative to EpiPen allergy shot approved by FDA